Navigation Links
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
Date:6/25/2008

to be studied in clinical trials for chronic pain. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis.

Webinar Information

Participants can access the Webinar by clicking on the link located on the home page of TorreyPines Therapeutics' Web site at http://www.torreypinestherapeutics.com. Individuals interested in asking questions should also participate via telephone by calling 888-823-7457 in the United States or 973-935-8504 outside of the United States and entering conference ID 48658866. Participants are encouraged to log on at least 15 minutes prior to the beginning of the Webinar. A replay of the Webinar will be available on TorreyPines Therapeutics' Web site until July 25.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarin
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
3. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
6. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... As of February, InControl Medical, LLC ... women. "Shipping thousands of our devices ... the hundreds of letters, emails and phone calls ... positively impacted by our technology," said Herschel ... recently released Apex, an over-the-counter solution for female ...
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
...   Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), ... president and chief executive officer of Pacira Pharmaceuticals, is scheduled ... Tuesday, September 20, 2011, at 11 a.m. EDT to be ... Center in New York City. Mr. Stack is expected to ...
... 2011 VIVUS, Inc. (NASDAQ: VVUS ) ... study in diabetics.  In the REVIVE-Diabetes study (TA-302), male ...  Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado ... study during the poster session at the 47th European ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference 2Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 2Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 3Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 4
(Date:3/27/2015)... Top medical tourism firm, VisitandCare.com ... the Dominican Republic to benefit from the experience of ... the medical tourism industry upside-down and becoming a choice ... services becoming the central influence. , “Trust is ... are not only attracted to low-cost surgical enhancement, but ...
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 DrugDev announced ... (Liss) Easy was named to the 2015 Philadelphia Business ... 40 list spotlights 40 dynamic, up-and-coming leaders less than ... community involvement. Winners are honored at an awards program ... the Philadelphia Business Journal. , Lyn Kremer, Publisher of ...
(Date:3/27/2015)... According to Health Day , ... Neonatal Abstinence Syndrome (NAS) are causing alarm for Florida ... withdrawal process for a month of their lives- and ... and vomiting. The condition is precipitated by drug use ... treatment (and employing medically assisted drug treatment) will also ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
Breaking Medicine News(10 mins):Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3
... Denise Mann HealthDay Reporter , MONDAY, July ... juice or capsules for the treatment and prevention of ... antibiotics may be more effective even if they contribute ... are less effective in the prevention, but do not ...
... 26, 2011] Antibiotic overuse and resistance have emerged as ... outbreak of Clostridium difficile infections, which often result from ... physicians and pharmacists with an education campaign that reduced ... Clinical Infectious Diseases and now available ...
... 2011Better data are needed to evaluate access to care ... as older African Americans, and to assess the benefits ... health information technology and access to multilevel diabetes education ... Management , a peer-reviewed journal published by Mary Ann ...
... July 25 (HealthDay News) -- Hospitalized patients who are able ... satisfied with their care, but one-fifth are not given the ... The authors of the new study compiled information on the ... three-year period, and had the patients rate their sense of ...
... MONDAY, July 25 (HealthDay News) -- The varicella vaccine has nearly ... study shows. The vaccine, introduced in a one-dose form ... all age groups and by 97 percent in young people 20 ... Immunization and Respiratory Diseases. "This is one of our ...
... Southwestern Medical Center researchers have narrowed the potential drug ... tumors are driven by a different hormonal pathway than ... known to stimulate the growth of the disease, advanced ... actually is driven by a pathway that circumvents the ...
Cached Medicine News:Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 2Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 3Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:New data-based strategies and treatment models can improve diabetes care for older African-Americans 2Health News:Spiritual Talks May Boost Patients' View of Hospital Care 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 3Health News:UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: